Open access
Oct 2026
Association of baseline glycaemic status with BMD change after 12 doses of romosozumab: a retrospective cohort study of 170 patients
We evaluated whether dysglycaemia is an independent factor associated with bone mineral density (BMD) gain during romosozumab treatment. We included all patients who initiated and received 12 doses of romosozumab in two Osteoporosis Centres from January 2019 to March 2025 and had dual-energy X-ray absorptiom...
K. H. Tsoi, Xiao-Qi Xiong, Xiao-Dong Liu et al.
· Frontiers in Endocrinology · 0 citations